Shopping Cart
- Remove All
Your shopping cart is currently empty
KRH102140 is a PHD2 activator that reduces angiogenesis by inhibiting HIF-1alpha, used in cardiovascular disease research.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $330 | In Stock | |
| 5 mg | $790 | In Stock | |
| 10 mg | $1,120 | In Stock | |
| 25 mg | $1,670 | In Stock | |
| 50 mg | $2,180 | In Stock |
| Description | KRH102140 is a PHD2 activator that reduces angiogenesis by inhibiting HIF-1alpha, used in cardiovascular disease research. |
| Targets&IC50 | 5-LOX:160 nM |
| In vitro | KRH102140 is a PHD2 activator that effectively inhibits HIF-1α in hypoxic human osteosarcoma cells. In addition, KRH102140 reduced mRNA levels of downstream target genes of HIF regulation related to angiogenesis and energy metabolism. [1] KRH102140 inhibited 5-LO activity with an IC50 value of 160 ± 23 nmol/l and inhibited LTB in RBL-1 cells. [2] |
| In vivo | Oral administration of KRH102140 (10-100 mg/kg) reduced ear edema, myeloperoxidase activity, and LTB production in a mouse inflammatory model. The oral bioavailability of rats was 66%. [2] |
| Synonyms | KRH 102140 |
| Molecular Weight | 373.46 |
| Formula | C25H24FNO |
| Cas No. | 864769-01-7 |
| Smiles | FC=1C=CC=CC1CNC=2C=CC=3OC(C=CC3C2)(C)CCC=4C=CC=CC4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (267.77 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.